Showing results (121-130 of 331) with videos related to
Sort By:
Pageof 34
NPJ Precision Oncology|January 21, 2022
Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patientsChi Yan, Sheau-Chiann Chen, Gregory D Ayers, et al.Journal for Immunotherapy of Cancer|August 5, 2020
Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanomaArissa C Young, Henry T Quach, Haocan Song, et al.Cancer Immunology Research|March 12, 2016
Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 TherapyAllison R Greenplate, Douglas B Johnson, Mikael Roussel, et al.Molecular & Cellular Proteomics : MCP|May 27, 2017
Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human MelanomaCarlos A Morales-Betanzos, Hyoungjoo Lee, Paula I Gonzalez Ericsson, et al.American Journal of Otolaryngology|May 8, 2025
Cost evaluation in head and neck cancer clinical trials: implications for high-value careRachel G Collins, Ina A Lee, Daniel R S Habib, et al.Molecular & Cellular Proteomics : MCP|April 19, 2017
WITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanomaCarlos A Morales-Betanzos, Hyoungjoo Lee, Paula I Gonzalez-Ericsson, et al.Journal of Leukocyte Biology|April 13, 2017
Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrowMikael Roussel, P Brent Ferrell, Allison R Greenplate, et al.Nature Reviews. Clinical Oncology|February 18, 2026
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalizationDouglas B Johnson, Amin H Nassar, Ayesha Aijaz, et al.The Oncologist|April 3, 2019
Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 TherapyHenry T Quach, Charles J Robbins, Justin M Balko, et al.The Lancet. Oncology|August 8, 2020
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and researchDouglas B Johnson, Kerry L Reynolds, Ryan J Sullivan, et al.Pageof 34